Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navacaprant
- Development stage
- Phase 3
- Lead developer
- Neumora Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Navacaprant is a small molecule, selective kappa opioid receptor antagonist being developed by Neumora Therapeutics for the treatment of major depressive disorder (MDD). It is designed to modulate dopamine and reward processing pathways. Navacaprant is administered orally at a dose of 80 mg once daily.
- Other names
- BTRX335140BTRX-335140BTRX 335140CYM53093CYM-53093CYM 53093XK5ILZ28KIXK-5ILZ28KIXK 5ILZ28KI
02
Targets
KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on navacaprant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navacaprant.